The Reporting Persons named in Item 2 below are hereby jointly filing this statement on
beneficial ownership on Schedule 13D (this Statement) because due to certain relationships among the Reporting Persons, such Reporting Persons may be deemed to beneficially own the same securities named in Item 4 below by one of
the Reporting Persons. In accordance with Rule 13d-1(k)(1)(iii) promulgated pursuant to the Securities Exchange Act of 1934, as amended (the Exchange Act), the Reporting Persons named in
Item 2 below have executed a written agreement relating to the joint filing of this Schedule 13D (the Joint Filing Agreement), a copy of which is attached as Exhibit 99.1 to this Statement.
Item 1. Security and Issuer.
This
Statement relates to the common stock, par value $0.0001 per share (the Common Stock), of Better Therapeutics, Inc., a Delaware corporation (the Issuer). The address of the Issuers principal executive
offices is 548 Market Street, #49404, San Francisco, CA 94104.
Item 2. Identity and Background.
(a) This Statement is being filed jointly by the following persons (each, a Reporting Person, and, collectively, the
Reporting Persons): (i) David P. Perry 2015 Trust, a Massachusetts trust (the Perry Trust), (ii) David P. Perry, the Executive Chairman of the Board of Directors of the Issuer
(Mr. Perry), (iii) Georgianna Maule-Ffinch, Mr. Perrys spouse (G. Maule-Ffinch) and (iv) Donald R. Leo, Trustee of Pensus Limited Trust dated 06/12/2010 FBO
Georgianna Maule-Ffinch, an Arizona trust (the Pensus Limited Trust).
(b) Mr. Perrys and G.
Maule-Ffinchs business address is c/o Better Therapeutics, Inc., 548 Market Street, #49404, San Francisco, CA 94104. The business address of the Perry Trust is c/o Blouin & Company, Inc., 2020 Commonwealth Ave., Newton, MA 02466. The
business address of the Pensus Limited Trust is 2390 East Camelback Rd., Phoenix, AZ 85016.
(c) Mr. Perry is the Executive Chairman
of the Board of Directors of the Issuer and serves as the sole trustee of the Perry Trust. The Perry Trust and the Pensus Limited Trust were created for estate planning purposes. The principal business of each of the Perry Trust and the Pensus
Limited Trust is holding, managing, investing and distributing the trust property and the proceeds therefrom.
(d) During the last five
years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the past five years, the Reporting Persons were not a party to any civil proceeding of a judicial or administrative body of
competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
(f) The Perry Trust is administered under the laws of Massachusetts. The Pensus Limited Trust is
administered under the laws of Arizona. Each of Mr. Perry and G. Maule-Ffinch is a citizen of the United States.
Item 3. Source of Funds.
The responses to Items 4 and 6 of this Statement are incorporated herein by reference.
Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the Merger Agreement), by and among
Mountain Crest Acquisition Corp. II (the former name of the Issuer, MCAD), MCAD Merger Sub Inc. (Merger Sub) and Better Therapeutics, Inc. (BTX), on October 28, 2021, Merger Sub merged
with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of the Issuer (such merger and the other transactions contemplated by the Merger Agreement, the Business Combination). The Issuer changed its name to
Better Therapeutics, Inc. upon the Business Combination and BTX changed its name to Better Therapeutics OpCo, Inc. preceding the Business Combination. The foregoing description of the Business Combination does not purport to be complete and is
qualified in its entirety by the full text of the Merger Agreement, which is attached as Exhibit 99.2 to this Statement and incorporated herein by reference.